Sayeli Jayade
Overview
Explore the profile of Sayeli Jayade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aguiar-Ibanez R, McQuarrie K, Jayade S, Penton H, DiGiovanni L, Raina R, et al.
Future Oncol
. 2024 Dec;
21(3):349-365.
PMID: 39676564
Background: Following an early-stage cancer diagnosis, recurrences can occur. To quantify financial impacts of a first recurrence, we surveyed patients and caregivers. Methods: The survey was self-administered online to patients...
2.
Bhutani T, Jayade S, Rege S, Penton H, Patel V, Kalirai S, et al.
J Dermatolog Treat
. 2024 Jun;
35(1):2366532.
PMID: 38914422
This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Residual disease was defined as experiencing moderate, severe, or...
3.
Armstrong A, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, et al.
Dermatol Ther (Heidelb)
. 2024 Jan;
14(2):421-439.
PMID: 38252376
Introduction: While multiple treatments are available for moderate to severe psoriasis, patient preferences are rarely systematically studied. This study aims to identify factors associated with choice of a new once-daily...
4.
Penton H, Jayade S, Selveindran S, Heisen M, Piketty C, Ulianov L, et al.
Dermatol Ther (Heidelb)
. 2023 Sep;
13(11):2549-2571.
PMID: 37747670
Introduction: Assessing treatment response is key to determining treatment value in atopic dermatitis (AD). Currently, response is assessed using various clinician- or patient-reported measures and response criteria. This variation creates...
5.
George D, Mohamed A, Tsai J, Karimi M, Ning N, Jayade S, et al.
Cancer Med
. 2022 Oct;
12(5):6040-6055.
PMID: 36226867
Background: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration-resistant prostate cancer (mCRPC) can facilitate shared-decision making for optimal management. This study sought to...
6.
Zeidan A, Tsai J, Karimi M, Schmier J, Jayade S, Zormpas E, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jun;
22(9):e853-e866.
PMID: 35729009
Introduction/background: Therapy with infused or injected hypomethylating agents (HMAs) may lead to higher treatment administration burden (ie, local reaction, visit frequency and duration) vs. oral HMAs. OBJECTIVES: To reveal preferences...
7.
Zeidan A, Jayade S, Schmier J, Botteman M, Hassan A, Ruiters D, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Oct;
22(3):e185-e198.
PMID: 34674983
Background: Until recently, patients with MDSs could receive HMAs via intravenous (IV) or subcutaneous (SC) administration. An oral HMA was recently approved as an alternative to IV/SC administration. This study...
8.
Yu W, Bajorek J, Jayade S, Miele A, Mirza J, Rogado S, et al.
J Biomed Mater Res A
. 2016 Sep;
105(1):311-318.
PMID: 27671834
In previous work, we observed that localized and sustained delivery of an anti-inflammatory drug, salicylic acid (SA), via a SA-based polymer (SAP) powder significantly enhanced diabetic bone regeneration through long-term...